Turing
Develop new consumer products remarkably fast.
Published Jul 4, 2026
| Starting Price | Not publicly listed (demo-led) | Not publicly listed (contact sales) | Public listing cites a service-level price for a related offering (scope differs from a full enterprise BIOVIA deployment) |
| Best For | CPG R&D teams seeking AI-guided formulation optimization and reduced experimental cycles with lower-data maturity | Innovation and formulation acceleration using AI models across concept to formulation | Enterprise customers needing comprehensive formulation management, governance, and scientific informatics integration |
| Key Strength | Domain-focused AI models and KPI-driven formulation workflows as presented by the vendor | Marketing-positioned end-to-end product development features and AI tooling | Mature enterprise platform with broad scientific and governance capabilities |
| Key Weakness | Limited independent public reviews; incomplete public integration and validation details; pricing not published | Pricing not public; regulatory and PLM depth not fully documented publicly | Potentially higher implementation overhead and total cost of ownership for smaller teams |
—
Turing and other AI-first innovators emphasize accelerating iteration and reducing physical testing. Differentiation among vendors will depend on model suitability for specific product categories, explainability, integration with existing R&D workflows, and the ability to support regulatory documentation.
Compared with PLM and formulation management suites (BIOVIA, Devex PLM), PLM vendors generally provide stronger governance, supplier collaboration, and global compliance workflows. The AI-layer vendors position themselves to reduce experimental volume and accelerate ideation, which buyers should validate through pilots that measure actual reduction in experiments and time to decision.
Independent press coverage documents fundraising and product announcements; broad adoption metrics remain predominantly vendor-asserted.